Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Catalio Capital Management
Deal Size : $90.0 million
Deal Type : Financing
Syndeio Biosciences Launches to Pioneer Synapse-Targeted Neurotherapeutics
Details : The net procceds will be used for Syndeio’s lead candidate, GATE-251 aka zelquistinel, an orally bioavailable positive allosteric modulator of the NMDA receptor, to treat major depressive disorder.
Product Name : GATE-251
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 27, 2025
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Catalio Capital Management
Deal Size : $90.0 million
Deal Type : Financing
Reset All
